As precision medicine and molecular cancer testing continue to advance, cross-border laboratory services and international collaborations have become key drivers of growth in the global healthcare industry. At BIO Asia–Taiwan 2026, EG BioMed will present its vision of “Bridging the U.S. and Global Markets,” showcasing an international precision cancer testing service platform built upon Taiwan-based innovation and U.S. CAP- and CLIA-certified laboratory resources.

EG BioMed has been actively developing DNA methylation biomarker technologies and molecular testing solutions while expanding its presence in the United States. The company operates a CLIA-certified and CAP-accredited clinical laboratory that serves as a foundation for international testing services and global collaborations.

Key exhibition highlights include:

• CAP- and CLIA-certified U.S. clinical laboratory resources
• International precision cancer testing service platform
• Global sample testing and logistics capabilities
• U.S. market partnership and business development opportunities

Through its U.S. laboratory infrastructure and international partnership network, EG BioMed delivers high-quality testing services that meet global standards while helping healthcare providers, research institutions, and industry partners accelerate innovation and access international markets.

In addition to strengthening its U.S. presence, the company continues to expand strategic partnerships worldwide by integrating technology, regulatory expertise, laboratory services, and commercial resources into a comprehensive precision cancer testing platform.

During BIO Asia–Taiwan 2026, EG BioMed welcomes hospitals, biotechnology companies, research organizations, and international partners to explore future opportunities in precision cancer testing, cross-border laboratory services, and global healthcare innovation.

“Starting from Taiwan innovation and leveraging U.S. infrastructure to build a global precision cancer testing network.”